Krystal Biotech (NASDAQ:KRYS) Shares Down 6.4% – Should You Sell?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price was down 6.4% during mid-day trading on Tuesday . The company traded as low as $345.00 and last traded at $340.2140. 39,718 shares traded hands during trading, a decline of 87% from the average session volume of 304,481 shares. The stock had previously closed at $363.44.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on KRYS shares. Citigroup increased their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Bank of America increased their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday. Wolfe Research began coverage on Krystal Biotech in a research report on Friday, March 27th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $360.67.

Krystal Biotech Stock Performance

The firm has a market cap of $10.08 billion, a P/E ratio of 45.70 and a beta of 0.50. The company has a 50 day moving average of $327.17 and a 200 day moving average of $287.07.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. As a group, analysts expect that Krystal Biotech, Inc. will post 7.66 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 over the last 90 days. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB boosted its position in shares of Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after acquiring an additional 39,000 shares in the last quarter. SG Americas Securities LLC increased its holdings in Krystal Biotech by 469.9% during the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock valued at $4,662,000 after purchasing an additional 15,591 shares in the last quarter. Fisher Asset Management LLC acquired a new stake in Krystal Biotech during the 4th quarter valued at $933,000. Principal Financial Group Inc. raised its position in Krystal Biotech by 15.6% in the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock valued at $40,697,000 after purchasing an additional 22,231 shares during the last quarter. Finally, Biondo Investment Advisors LLC raised its position in Krystal Biotech by 31.3% in the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock valued at $16,797,000 after purchasing an additional 16,245 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.